NCT05827835

CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

A Study to Evaluate the Efficacy and Safety of CD7CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed CD7 Positive Malignant Hematologic Diseases

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases

Conditions

• Hematologic Diseases
• Neoplasms

Interventions

Type	Name	Description
DRUG	CD7 CAR-T cells injection	CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
OTHER	Allogeneic hematopoietic stem cell transplantation	In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases

Timeline

• Start date: 2023-04-30
• Primary completion: 2026-04-25
• Completion: 2027-04-25
• First posted: 2023-04-25
• Last updated: 2025-08-13

Locations

1 site across 1 country: China